Panelists discuss how subcutaneous (SubQ) and intravenous (IV) oncology therapies will continue to coexist, with patient-specific factors guiding delivery method choices, while ongoing innovation and ...

When deciding whether to use subcutaneous (SubQ) or intravenous (IV) therapies, clinicians must weigh several clinical and practical factors. One of the first considerations is the type of cancer ...

BCS: Radiological Tests Little Use in Detecting Breast Mets For human epidermal growth factor receptor 2 (HER2)-positive early breast cancer, a subcutaneous formulation of trastuzumab is non-inferior ...

Roche’s Lunsumio may be the first CD20xCD3 T-cell engager approved by the FDA, but intravenous administration puts the drug at a disadvantage to AbbVie and Genmab’s subcutaneously injected Epkinly.

Please provide your email address to receive an email when new articles are posted on . Subcutaneous tocilizumab provides similar exposure and risk-benefit profiles as intravenous tocilizumab in ...

– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...